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Use and Outcomes Associated With Perioperative Amiodarone in
Cardiac Surgery
Auras R. Atreya, MD, MPH; Aruna Priya, MA, MSc; Quinn R. Pack, MD, MSc; Penelope S. Pekow, PhD; Mihaela Stefan, MD, PhD; Tara Lagu,
MD, MPH; Amir S. Lotfi, MD; Peter K. Lindenauer, MD, MSc
Background-—In randomized controlled trials, perioperative administration of amiodarone has been shown to reduce the incidence
of postoperative atrial arrhythmias and length of stay (LOS) among patients undergoing coronary bypass surgery. However, little is
known about the use or effectiveness of perioperative amiodarone in routine clinical practice.
Methods and Results-—We studied patients ≥18 years old without a previous history of atrial or ventricular arrhythmias who
underwent elective coronary bypass surgery between 2013 and 2014within a network of 235 US hospitals. Perioperative amiodarone
was defined as receipt of amiodarone either on the day of or the day preceding surgery. We used covariate-adjusted modeling and
instrumental variable methods to examine the association between receipt of amiodarone and the development of atrial arrhythmias,
in-hospital mortality, readmission, LOS, and cost. Of 12 758 patients, 2195 (17.2%) received perioperative amiodarone, 3330 (26.1%)
developed atrial arrhythmias postoperatively, and the average LOS was 6.4 days (2.6 days). Instrumental variable analysis showed
that receipt of perioperative amiodarone was associated with lower risk of atrial arrhythmias (risk difference11 percentage points,
95% CI19 to4 percentage points; P=0.002) and a shorter LOS (0.7 day, 95% CI1.39 to0.01 days; P=0.048). There was no
association between receipt of perioperative amiodarone and in-hospital mortality, cost, or readmission.
Conclusions-—Among patients undergoing coronary bypass surgery without previous arrhythmias, perioperative amiodarone is
associated with a lower risk of atrial arrhythmias and shorter LOS. These findings are consistent with previous randomized trials and
lend support to current guideline recommendations. ( J Am Heart Assoc. 2019;8:e009892. DOI: 10.1161/JAHA.118.009892.)
Key Words: amiodarone • atrial fibrillation arrhythmia • coronary artery bypass graft surgery • heart valve surgery •
postoperative complication arrhythmia
P ostoperative atrial fibrillation and atrial flutter are themostcommon arrhythmic complications following cardiac
surgery, affecting 25% to 50% of patients in the postoperative
period.1-3 Atrial arrhythmias typically develop on the second or
third postoperative day, and regardless of treatment, they
generally resolve within 6 to 8 weeks of surgery.2 In addition to
discomfort, anxiety, and hemodynamic instability, the devel-
opment of postoperative atrial arrhythmias has been associ-
ated with longer length of stay (LOS) and higher hospital
costs.4-6 Observational studies conducted in the 1990s
suggested that atrial arrhythmias were associated with a 3-
to 5-day longer LOS,5,7-9 but more recent analyses have found
that this association is weaker or even absent, possibly a
reflection of changing postoperative management of atrial
arrhythmias and discharge practices.10,11
Strategies to prevent postoperative atrial arrhythmias
include both pharmacological agents and nonpharmacological
interventions.2,11-13 The 2011 American College of Cardiol-
ogy/American Heart Association/Heart Rhythm Society atrial
fibrillation management guidelines recommend b-blockers for
all patients without contraindications (class I, level A) and
amiodarone in patients at high risk for atrial arrhythmias
(class IIa, level A).2 The basis of the recommendation for
amiodarone use is largely derived from reduction of atrial
arrhythmias noted in randomized controlled trials (both
preoperative and postoperative amiodarone use), the largest
and the most recent of which was PAPABEAR (Prophylactic
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Amiodarone for the Prevention of Arrhythmias that Begin Early
After Revascularization, Valve Replacement, or Repair trial).14
In this study consisting of 601 patients, a perioperative
course of oral amiodarone demonstrated a significant reduc-
tion in the incidence of postoperative atrial tachyarrhythmia
(13.4% absolute risk reduction). A meta-analysis of 19
randomized controlled trials, including 3396 patients, showed
that amiodarone reduces atrial arrhythmias (pooled odds ratio
0.50, 95% CI 0.43-0.59).15 This study also showed a modest
reduction in hospital LOS in the amiodarone group (pooled
difference of 0.6 days in the amiodarone group, 95% CI 0.4-
0.8).
Although amiodarone is recommended in guidelines, little is
known about the use of amiodarone among patients undergoing
cardiac surgery in theUnited States or if the benefits reported in
randomized controlled trials have been achieved in routine
clinical practice. We therefore investigated the application of
perioperative amiodarone use among patients admitted for
elective cardiac surgery in a large network of US hospitals and
compared the outcomes of those receiving perioperative
amiodarone to those who did not. We hypothesized that
perioperative amiodarone would be associated with a lower
incidence of atrial arrhythmias but not with healthcare utiliza-
tion outcomes such as LOS, cost, or readmission.
Methods
The authors declare that all supporting data are available
within the article and its online supplementary files. Based on
our data use agreement with the Premier Analytic Database,
we are unable to share the primary data set; however, we can
make the data analyses from our statistical programs
available on specific request (Peter.Lindenauer@baystate-
health.org).
Setting and Subjects
We conducted a retrospective cohort study of patients
admitted between January 1, 2013 and December 31, 2014
to a geographically and structurally diverse set of hospitals
participating in Premier Incorporated’s Perspective (Premier
Healthcare Informatics, Charlotte, NC), a voluntary, fee-
supported database developed for measuring quality and
healthcare utilization. In addition to the information available
in the standard hospital discharge file, the Perspective
database contains date-stamped logs of all billed items,
including medications, laboratory, diagnostic, and therapeutic
services at the individual patient level. Diagnostic and
procedural information was assessed using International
Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM).
Patients were included in our analysis if they were
18 years or older and underwent elective coronary artery
bypass surgery (CABG; ICD-9 procedure codes 36.1x,
x=0,1,2,3,4,5,6,7,9) alone or CABG with concomitant heart
valve surgery (ICD-9 procedure codes 35.1x, x=0,1,2,3,4 or
35.2x, x=0,1,2,3,4,5,6,7,8) on the first or second day of their
hospitalization. To address the clinical question of whether
prophylactic use of amiodarone is effective at preventing
arrhythmia, we excluded patients with a previous history of
atrial or ventricular arrhythmias (including atrial fibrillation,
atrial flutter [427.31, 427.32], ventricular tachycardia/fibril-
lation [427.1, 427.4x, x=1,2]) or anyone with these codes
present on admission. We also excluded those who had
received treatment with class I and class III antiarrhythmic
drugs (disopyramide, lidocaine, dofetilide, dronedarone,
digoxin, sotalol, flecainide, propafenone, mexiletine, ibutilide,
procainamide) during an earlier admission or before surgery
during the index admission. On similar grounds we excluded
patients who had received amiodarone during a previous
admission. Patients with chronic obstructive pulmonary
disease severe enough to require hospitalization in the past
year and those with hypotension or bradycardia at admission
were also excluded from the cohort, as these conditions may
have represented contraindications to amiodarone treatment.
Individuals with a pacemaker were excluded from the cohort
because we wished to study pacemaker implantation as an
outcome. Last, since our secondary goal was to make
inferences about interactions between amiodarone and b-
blocker use, we excluded b-blockers that may have been used
for other purposes (eg, intraoperative blood pressure control,
glaucoma prevention) and included only patients receiving
Clinical Perspective
What Is New?
• Previous small randomized controlled studies have established
the benefit of perioperative amiodarone in reducing atrial
arrhythmias and length of stay (LOS) following cardiac surgery.
• This is the first large observational study to examine the
association between amiodarone treatment and outcomes
in routine clinical practice.
What Are the Clinical Implications?
• Our analyses suggest that perioperative amiodarone was
both safe and effective at reducing the occurrence of
postoperative atrial arrhythmias, and receipt was associated
with a shorter LOS.
• At the same time, use of perioperative amiodarone remains
limited in clinical practice. Future efforts should focus on
consistent implementation of perioperative amiodarone
protocols, with appropriate patient selection in order to
achieve optimal surgical outcomes.
DOI: 10.1161/JAHA.118.009892 Journal of the American Heart Association 2
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metoprolol, carvedilol, bisoprolol, atenolol, labetolol, and
propranolol.
Permission to conduct the study was obtained by the
Institutional Review Board at Baystate Medical Center, where
the study was conducted, and the need for written informed
consent was waived (IRB# 777703-1).
Patient and Hospital Information
In addition to patient age, sex, race/ethnicity, and insurance
status, we recorded the presence of up to 29 unique
comorbidities using software provided by the Healthcare
Costs and Utilization Project of the Agency for Healthcare
Research and Quality (Rockville, MD) based on methods
described by Elixhauser et al.16 Comorbidity burden was
summarized as a score using methods described by Gagne
et al.17 For each hospital that participated in the study, we
recorded bed size, teaching status, geographic region, and
whether it served an urban or rural population.
Use of Amiodarone and Other Treatments
We considered a patient to have received perioperative
amiodarone if there was a pharmacy charge for treatment
with amiodarone either on the day of or day before surgery.
Patients whose first exposure to amiodarone began on or
after postoperative day 1 were classified as not having
received perioperative amiodarone because this may have
represented treatment for new-onset atrial arrhythmias or
another arrhythmia rather than for prophylaxis. To control for
differences in severity of illness not accounted for by age and
comorbidity, as well as the effects of other therapies, we
assessed the use of a wide range of diagnostic tests,
monitoring devices, and pharmacologic treatments adminis-
tered before surgery, including loop diuretics, angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers,
statins, nonsteroidal anti-inflammatory drugs, b-blockers, and
number of vessels bypassed during CABG.
Outcomes
The primary outcome was the occurrence of postoperative
atrial arrhythmia during the index admission, which was
defined based on an ICD-9 discharge diagnosis code of atrial
fibrillation or flutter that was not present on admission.
Secondary outcomes included in-hospital mortality, all-cause
readmission within 1 month (among survivors), LOS, and
hospital costs. In addition, we also examined a set of
cardiovascular outcomes that might be influenced by amio-
darone, including ventricular arrhythmias, stroke, myocardial
infarction, hypotension, bradycardia, heart block, pacemaker
implantation, cardiogenic shock, and cardiac arrest (not
present on admission). These outcomes were assessed using
ICD-9 diagnosis codes (Table S1).
Statistical Analyses
Patient and hospital characteristics were summarized as
frequencies: percentages for categorical variables and means
with standard deviations or medians with interquartile ranges
for continuous variables. Because of the large sample size, we
compared the characteristics of patients treated with periop-
erative amiodarone and patients who did not receive periop-
erative amiodarone (or received it after postoperative day 1)
via absolute standardized differences.18 A difference greater
than 10% was considered to represent significant imbalance
between the groups.
To analyze the association between perioperative amio-
darone and the study outcomes, we developed multivariable
adjusted generalized estimating equation models accounting
for patient clustering within hospitals. Logit link models were
used for binary outcome models, and identity link models
used for continuous outcomes. Our primary outcome, atrial
arrhythmia, was frequent in the cohort (>20%); therefore, we
assessed this outcome using Poisson models with log link
function to estimate a risk ratio. LOS and costs were skewed,
so we winsorized these outcomes at their 95th percentile
value. A propensity score analysis was also completed but
was not presented because it failed to balance important
confounder differences.19,20
Instrumental Variable Analyses
To address concerns regarding the possibility of residual
confounding by unmeasured factors (in which patients
receiving amiodarone would be at higher risk of arrhythmias),
we performed an instrumental variable analysis using hospital
preference for amiodarone as our instrument. To obtain stable
estimates of hospital amiodarone prescribing, we first
restricted the cohort to hospitals with at least 25 surgical
admissions. We then divided hospitals into quintiles, based on
the frequency of perioperative amiodarone use among
patients undergoing cardiac surgery. Hospital use of periop-
erative amiodarone defined our instrument, with patients
treated at hospitals in the upper 2 quintiles having a high
likelihood of perioperative amiodarone and patients at
hospitals in the bottom 3 quintiles having a low likelihood
of perioperative amiodarone. We performed 2-stage least-
squares regression to estimate the risk difference, the
absolute difference in risk of outcome among patients at
high- versus low-use hospitals. In the first stage, receipt of
perioperative amiodarone was modeled as a function of the
instrument and confounders, and in the second stage, the
outcome was modeled as a function of predicted treatment
DOI: 10.1161/JAHA.118.009892 Journal of the American Heart Association 3
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from the first-stage model as well as the confounders. The
strength of the instrument was measured using the partial F
statistic and partial R2 from stage 1 of the models.
Improvement in balance of patient characteristics in the
instrumental variable subcohort was assessed via absolute
standardized differences. Because the instrument was defined
based on hospital use of perioperative amiodarone, to address
the possibility of association of the instrument with outcomes,
we adjusted all models for hospital characteristics along with
patient factors that had a standardized difference of greater
than 10% in the instrumental variable cohort. We performed
the Durbin-Wu-Hausman test to confirm whether receipt of
perioperative amiodarone was correlated with other variables
in the model to confirm the value of instrumental variable
methods.21,22
All analyses were performed using the Statistical Analysis
System (version 9.3, SAS Institute, Inc, Cary, NC) and STATA
13 (StataCorp, LLC, College Station, TX).
Results
Of 12 758 patients who met our enrollment criteria (Figure 1),
10 409 (81.6%) at 235 hospitals were admitted for elective
CABG alone, while the remaining underwent combined
CABG+heart valve surgery. The mean age was 66 years, 75%
were male, 73% were white, and Medicare was the most
common form of health insurance (Table 1). Hypertension,
diabetes mellitus, obesity, heart failure, and peripheral vascular
disease were the most frequently recorded comorbidities.
Overall, 58% of patients were cared for at nonteaching facilities;
91% of hospitals were urban, and over 90% of the hospitals
operated more than 200 beds. The average LOS was 6.4 days,
average costs were $33 821, and 3 out of 10 patients were
hospitalized for 7 days or longer. A total of 3330 patients
(26.2%) developed an atrial arrhythmia during the index
admission, 167 (1.3%) died during the hospitalization, and
1653 (13.1%) were readmitted within 1 month of discharge
(Table 1). Receipt of warfarin before discharge was higher
among patients who had developed atrial arrhythmias than
among those who had not (32.9% versus 6.4%).
Use of Amiodarone and Other Treatments
In all, 2195 (17.2%) patients received perioperative amiodarone
on either the day of or day before cardiac surgery. The mean
duration of amiodarone received was 5.2 days, and mean dose
received during the hospitalization was 3.8 g of amiodarone.
When compared with those who did not receive perioperative
amiodarone, treated patients were slightly younger, more likely
n=28,478 adult paents ≥ 18 years with elecve admission for coronary artery bypass 
surgery/heart valve surgery on days 1 or 2 of hospitalizaon during 2013-2014
n=4,092 atrial fibrillaon/fluer present on admission or 
prior to index admission
n=332 ventricular fibrillaon/tachycardia present on 
admission or prior to index admission
n=9,344 received an-arrhythmic drugs during prior 
admissions or prior to surgery in index admission
n=46 presence of pacemaker prior to cardiac surgery
n=61 chronic obstrucve pulmonary disease requiring 
hospitalizaon in the year prior to surgery
n=173 hypotension or bradycardia present on admission
n=1,672 received non-cardiac betablockers
n=12,758 adult paents meeng eligibility criteria for our study (admied to 235 hospitals) 
n=15,720 excluded
n=10,563 did not receive peri-operave amiodarone
n=2,195 received peri-operave amiodarone 
Figure 1. Patient selection flow diagram.
DOI: 10.1161/JAHA.118.009892 Journal of the American Heart Association 4
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Difference (%)†12 758 (100) 10 563 (82.8) 2195 (17.2)
Patient characteristics
Age, mean (SD), y 66.0 (10.1) 66.1 (10.1) 65.3 (10.0) 7.5
Sex
Female 3154 (24.7) 2580 (24.4) 574 (26.2) 4
Race/ethnicity
White 9285 (72.8) 7466 (70.7) 1819 (82.9) 32.4
Black 700 (5.5) 586 (5.5) 114 (5.2)
Hispanic 628 (4.9) 551 (5.2) 77 (3.5)
Other 2145 (16.8) 1960 (18.6) 185 (8.4)
Insurance payer
Medicare 7288 (57.1) 6036 (57.1) 1252 (57.0) 14.4
Medicaid 759 (5.9) 642 (6.1) 117 (5.3)
Managed care 3262 (25.6) 2764 (26.2) 498 (22.7)
Other 1449 (11.4) 1121 (10.6) 328 (14.9)
Type of procedure
CABG 10 409 (81.6) 8620 (81.6) 1789 (81.5) 0.3
CABG+Valve 2349 (18.4) 1943 (18.4) 406 (18.5)
Gagne combined score, mean (SD) 1.6 (2.2) 1.7 (2.2) 1.6 (2.3) 2.5
Comorbidities
Hypertension 10 939 (85.7) 9088 (86) 1851 (84.3) 4.8
Tobacco abuse 6174 (48.4) 5013 (47.5) 1161 (52.9) 10.9
Diabetes mellitus 5722 (44.9) 4755 (45) 967 (44.1) 1.9
Obesity 3136 (24.6) 2563 (24.3) 573 (26.1) 4.2
Chronic pulmonary disease 2641 (20.7) 2067 (19.6) 574 (26.2) 15.7
Congestive heart failure 2225 (17.4) 1821 (17.2) 404 (18.4) 3.1
Peripheral vascular disease 2033 (15.9) 1687 (16) 346 (15.8) 0.6
Renal failure 1784 (14) 1499 (14.2) 285 (13) 3.5
Obstructive sleep apnea 1648 (12.9) 1322 (12.5) 326 (14.9) 6.8
Hypothyroidism 1353 (10.6) 1103 (10.4) 250 (11.4) 3
Depression 1035 (8.1) 833 (7.9) 202 (9.2) 4.7
Early therapies and tests‡
b-Blockers on or before surgery 5729 (44.9) 4445 (42.1) 1284 (58.5) 33.3
Statins 3459 (27.1) 2484 (23.5) 975 (44.4) 45.3
Loop diuretics 2025 (15.9) 1584 (15) 441 (20.1) 13.4
Cardiac catheterization before surgery 1603 (12.6) 1289 (12.2) 314 (14.3) 6.2
CABG: number of vessels bypassed
4 Arteries 1317 (10.3) 1074 (10.2) 243 (11.1) 11.2
3 Arteries 3193 (25) 2624 (24.8) 569 (25.9)
2 Arteries 4377 (34.3) 3591 (34) 786 (35.8)
1 Artery 2946 (23.1) 2463 (23.3) 483 (22)
Not specified 925 (7.3) 811 (7.7) 114 (5.2)
Continued
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to be white, and less likely to have private insurance (Table 1).
The 2 groups were comparable in terms of comorbidities;
however, patients treated with perioperative amiodarone were
more likely to receive b-blockers, angiotensin-converting
enzyme inhibitors, and statins in the first 2 hospital days.
There were no significant differences in terms of the number of
vessels bypassed during CABG. Treatment with perioperative
amiodaronewasmore common at urban, nonteaching hospitals
and at hospitals in the West.
Unadjusted and Multivariable Adjusted Outcomes
Outcomes from the unadjusted and covariate adjusted
analysis are presented in Figure 2. In the adjusted model,
atrial arrhythmias occurred in 23.4% of patients treated with
perioperative amiodarone as compared with 26.7% of
patients not receiving perioperative amiodarone (P<0.001).
There were no differences in the percentage of patients
readmitted within 1 month of discharge (12.5% versus
13.3%, P=0.3) or in inpatient mortality (1.6% versus 1.2%,
P=0.2) between the patients receiving perioperative amio-
darone and those not receiving perioperative amiodarone.
However, patients receiving perioperative amiodarone were
more likely to experience ventricular arrhythmias (4.3%
versus 2.8%, P<0.001). Although we did not observe clinically
meaningful differences in the hospital LOS between the 2
groups, total costs associated with the group treated with








Difference (%)†12 758 (100) 10 563 (82.8) 2195 (17.2)
Hospital characteristics
Number of beds
≤200 beds 942 (7.4) 790 (7.5) 152 (6.9) 39.3
201 to 400 beds 3900 (30.6) 2896 (27.4) 1004 (45.7)
≥401 beds 7916 (62.0) 6877 (65.1) 1039 (47.3)
Population served
Urban 11 620 (91.1) 9554 (90.4) 2066 (94.1) 13.8
Rural 1138 (8.9) 1009 (9.5) 129 (5.9)
Hospital region
Northeast 2795 (21.9) 2492 (23.6) 303 (13.8) 43.1
Midwest 2791 (21.9) 2501 (23.7) 290 (13.2)
West 1741 (13.6) 1326 (12.5) 415 (18.9)
South 5431 (42.6) 4244 (40.2) 1187 (54.1)
Teaching status
Nonteaching 5316 (41.7) 4164 (39.4) 1152 (52.5) 26.4
Teaching 7442 (58.3) 6399 (60.6) 1043 (47.5)
Outcomes in full cohort (adjusted) P Value||
Atrial arrhythmias§ 3330 (26.2) 2818 (26.7) 512 (23.4) <0.001
Ventricular arrhythmias 394 (3.1) 299 (2.8) 95 (4.3) <0.001
Readmission (all cause) within 1 mo 1653 (13.1) 1383 (13.3) 270 (12.5) 0.34
In-hospital mortality 167 (1.3) 132 (1.2) 35 (1.6) 0.2
LOS, mean (SD), days, winsorized at 95th percentile 6.36 (2.64) 6.36 (2.63) 6.37 (2.71) 0.44
Cost, mean (SD), USD, winsorized at 95th percentile 33 821 (13 216) 33 515 (13 107) 35 295 (13 636) <0.001
CABG indicates coronary artery bypass surgery; LOS, length of stay.
*Perioperative amiodarone is defined as amiodarone administered on same day or day preceding surgery.
†For continuous variables, absolute standardized difference ¼ 100 ðxtreatment  xcontrolÞ=sqrtð½s2treatment þ s2control=2Þ where x is sample mean in respective groups and s2 is sample variance in
respective groups. For binary variables: 1009(ptreatmentpcontrol)/sqrt([ptreatment9(1ptreatment)]+[pcontrol9(1pcontrol)]/2) where p is the prevalence of binary variable in treatment and
control groups, respectively. For categorical variables, multivariate Mahalanobis distance is computed.
‡Early therapies and tests are defined as treatment/test on same day or day preceding surgery.
§Atrial arrhythmias are defined as postoperative atrial fibrillation or flutter (not present on admission).
||P-value assessed via chi-squared test for binary outcomes and Kruskal-Wallis test for continuous outcomes.
DOI: 10.1161/JAHA.118.009892 Journal of the American Heart Association 6
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(95% CI $1250-$2483) higher than those for the group that
did not receive perioperative amiodarone (P<0.001).
Instrumental Variable Analyses
For the instrumental variable analysis, our cohort was
restricted to hospitals with at least 25 surgical admissions.
We identified 11 786 patients who underwent cardiac
surgery in 129 hospitals of whom 17.0% had received
perioperative amiodarone. Of these, 52 hospitals had high
perioperative amiodarone use (upper 2 quintiles of amio-
darone use), where 4083 patients received treatment.
Hospitals in the upper 2 quintiles treated 44.2% of their
patients with perioperative amiodarone compared with 2.6%
in the hospitals with low amiodarone use (lowest 3
quintiles). Hospitals with higher use were more likely to
be small or medium sized, nonteaching, and from the South
(Table 2). Results of the instrumental variable analysis
(Table 3) suggested that among marginal patients (those
whose treatment status can be affected by their choice of
hospital: low use of amiodarone versus hospitals with high
amiodarone use), receipt of perioperative amiodarone was
associated with a lower incidence of atrial arrhythmias (risk
difference 11 percentage points, 95% CI 19 to 4.0
percentage points; P=0.002) and with shorter LOS (risk
difference 0.7 days, 95% CI 1.39 to 0.01 days;
P=0.048). In contrast to the covariate-adjusted model, the
instrumental variable analysis did not find a higher risk of
ventricular arrhythmias associated with receipt of perioper-
ative amiodarone in the overall instrumental variable cohort.
However, differences were noted in hospitals with low
amiodarone use and high amiodarone use. Ventricular
arrhythmias were more common at hospitals with low
amiodarone use than high use (3.6% versus 2.3%, P=0.02)
(Table 2) and statistical testing for homogeneity indicated
differences in the 2 groups (odds ratio=4.5, 95% CI 3.0-6.9
versus odds ratio=2.3, 95% CI 1.5-3.6; P=0.024 for
Breslow-Day test for homogeneity).
There were no associations detected between the hospital
group where treatment was received (low-use of amiodarone
versus high-use hospital) and the risk of in-hospital mortality, 1-
month readmission, hospital cost, or any of the other cardio-
vascular outcomes, including cardiogenic shock and cardiac
arrest.
a Unadjusted outcomes (generalized esmang equaon/ GEE model accounng for paent 
clustering within hospital)
b Covariate adjusted- generalized esmang equaon model (GEE model accounng for paent 
clustering within hospital)
Figure 2. Forest plot of outcomes from various models. a indicates unadjusted outcomes GEE model/GEE
model accounting for patient clustering within hospital; b, covariate-adjusted GEE model/GEE model
accounting for patient clustering within hospital; GEE, generalized estimating equation; POA, present on
admission.
DOI: 10.1161/JAHA.118.009892 Journal of the American Heart Association 7
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Table 2. Patient Demographics, Treatments, and Hospital Characteristics in Instrumental Variable Analysis Cohort
Patient Characteristics
Hospitals in Lowest 3 Quintiles
of Perioperative Amiodarone
use (77 hospitals; 59.7%)





Number of patients 7703 (65.4) 4083 (34.6)
Perioperative amiodarone† use 201 (2.6) 1806 (44.2)
Age, mean (SD), y 66.4 (10.0) 65.3 (10.1) 11.6
Sex
Female 1883 (24.4) 1030 (25.2) 1.8
Race/ethnicity
White 5468 (71) 3185 (78) 18.5
Black 410 (5.3) 226 (5.5)
Hispanic 397 (5.2) 126 (3.1)
Other 1428 (18.5) 546 (13.4)
Insurance payer
Medicare 4478 (58.1) 2276 (55.7) 13
Medicaid 424 (5.5) 277 (6.8)
Managed care 2016 (26.2) 964 (23.6)
Other 785 (10.2) 566 (13.9)
Type of procedure
CABG 6103 (79.2) 3463 (84.8) 14.6
CABG+Valve 1600 (20.8) 620 (15.2)
Gagne combined score, mean (SD) 1.7 (2.2) 1.5 (2.2) 9.2
Comorbidities
Hypertension 6572 (85.3) 3529 (86.4) 3.2
Tobacco abuse 3528 (45.8) 2184 (53.5) 15.4
Diabetes mellitus 3421 (44.4) 1833 (44.9) 1
Obesity 1858 (24.1) 1044 (25.6) 3.4
Chronic pulmonary disease 1441 (18.7) 996 (24.4) 13.9
Congestive heart failure 1362 (17.7) 673 (16.5) 3.2
Peripheral vascular disease 1231 (16) 646 (15.8) 0.4
Renal failure 1086 (14.1) 555 (13.6) 1.5
Obstructive sleep apnea 967 (12.6) 571 (14) 4.2
Hypothyroidism 833 (10.8) 430 (10.5) 0.9
Depression 594 (7.7) 367 (9) 4.6
Early therapies and tests‡
b-Blockers on or before surgery 3165 (41.1) 2106 (51.6) 21.2
Loop diuretics 1049 (13.6) 844 (20.7) 18.8
Statins 1816 (23.6) 1345 (32.9) 20.9
Cardiac catheterization before surgery 946 (12.3) 511 (12.5) 0.7
CABG: number of vessels bypassed
4 arteries 827 (10.7) 381 (9.3) 6.6
3 arteries 1902 (24.7) 1028 (25.2)
2 arteries 2602 (33.8) 1453 (35.6)
1 artery 1827 (23.7) 909 (22.3)
Not specified 545 (7.1) 312 (7.6)
Continued
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Discussion
In this large national cohort of more than 12 000 patients
undergoing cardiac surgery, receipt of perioperative amio-
darone was associated with lower risk of atrial arrhythmias
and shorter hospital LOS. We found no association with
inpatient mortality, readmission, or hospital cost in our
primary analysis. These results were confirmed in an instru-
mental variable analysis (based on hospital preference for
amiodarone therapy). Our results are generally consistent
with previous meta-analyses and randomized clinical tri-
als.15,23 Because patients enrolled in randomized studies are
highly selected, and trial participants receive protocolized
care, it is critical to demonstrate the generalizability of these
findings in routine clinical settings. It is not uncommon to find
differences in the magnitude and occasionally the direction of
effects between randomized clinical trials and large observa-
tional studies.24 In this largest observational study to date of
perioperative amiodarone use, we observed benefits of
amiodarone treatment that are consistent with the findings
of previous randomized studies and that lend support to
current guideline recommendations.
Atrial Arrhythmias Following Cardiac Surgery
A number of small randomized controlled studies have shown
reduction of atrial arrhythmias with the use of perioperative
amiodarone. Of note, earlier randomized controlled studies
differed substantially in the amiodarone protocols utilized.
There have been 9 studies that initiated amiodarone
Table 2. Continued
Patient Characteristics
Hospitals in Lowest 3 Quintiles
of Perioperative Amiodarone
use (77 hospitals; 59.7%)







≤200 beds 503 (6.5) 353 (8.6) 45.4
201 to 400 beds 1752 (22.7) 1713 (41.9)
≥401 beds 5448 (70.7) 2017 (49.4)
Population served
Urban 7036 (91.3) 3693 (90.4) 3.1
Rural 667 (8.7) 390 (9.5)
Hospital region
Northeast 2143 (27.8) 535 (13.1) 65.3
Midwest 2072 (26.9) 511 (12.5)
West 607 (7.9) 852 (20.9)
South 2881 (37.4) 2185 (53.5)
Teaching status
Nonteaching 2643 (34.3) 2084 (51.0) 34.3
Teaching 5060 (65.7) 1999 (49.0)
Outcomes P Value§
Atrial arrhythmias 2210 (28.7) 884 (21.7) <0.001
Ventricular arrhythmias 275 (3.6) 93 (2.3) 0.02
Readmission (all cause) within 1 mo 971 (12.8) 544 (13.5) 0.57
In-hospital mortality 106 (1.4) 51 (1.2) 0.62
LOS, mean (SD), days, winsorized at 95th percentile 6.4 (2.5) 6.0 (2.5) 0.01
Cost, mean (SD), USD, winsorized at 95th percentile 33 380 (13 140) 34 116 (13 011) 0.60
CABG indicates coronary artery bypass surgery; LOS, length of stay.
*For continuous variables: absolute standardized difference ¼ 100 ðxtreatment  xcontrolÞ=sqrtð½s2treatment þ s2control=2Þ where x is sample mean in respective groups and s2 is sample variance in
respective groups. For binary variables: 1009(ptreatmentpcontrol)/sqrt([ptreatment9(1ptreatment)]+[pcontrol9(1pcontrol)]/2) where p is the prevalence of a binary variable in treatment and
control groups, respectively. For categorical variables, multivariate Mahalanobis distance is computed.
†Perioperative amiodarone is defined as amiodarone administered on same day or day preceding surgery.
‡Early therapies and tests are defined as treatment/test on the same day or day preceding surgery.
§P-value from 2-stage least squares (unadjusted for patient characteristics).
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preoperatively (ranging from 1 to 14 days preoperatively) and
10 studies that initiated amiodarone either intraoperatively or
exclusively in the postoperative phase (maximum of 28 days
postoperatively).15 Apart from the PAPABEAR trial (n=601), all
these studies were small, enrolling between 70 and 315
patients. As a result, findings from meta-analyses are heavily
weighted by the PAPABEAR trial, which utilized a preoperative
amiodarone regimen (10 mg/kg daily beginning 6 days before
and continuing for 6 days after surgery)14. Irrespective of the
amiodarone regimen, all studies noted some degree of
decrease in the incidence of atrial arrhythmias (absolute risk
reductions ranging from 2% to 28%), but secondary outcomes of
interest such as mortality, LOS, and readmissions varied
(possibly due to low power for secondary outcomes).15 In
comparison, our observational study of a large, contemporary
cohort, including 2195 patients who received perioperative
amiodarone found an 11% risk reduction in atrial arrhythmias,
which is comparable to the 13.4% absolute risk reduction noted
in the PAPABEAR trial.14
Healthcare Utilization Outcomes Following
Cardiac Surgery
Although amiodarone therapy was associated with lower
incidence of atrial arrhythmias and modestly shorter hospital
LOS, this did not translate into lower readmission rate or
reduced hospital costs. At first glance thismay seem surprising,
but previous studies have found similar results. Historically,
there have been conflicting data about the association of atrial
arrhythmias with LOS.10 Additionally, interventions (amio-
darone, sotalol, procainamide, overdrive pacing) intended to
reduce atrial arrhythmias have had inconsistent effects on
LOS,25 and a Cochrane review of 58 trials of varying interven-
tions did not find a significant effect of these treatments on
LOS.11 Even when the focus is on amiodarone as the
prophylactic strategy, the meta-analysis by Bagshaw et al15
showed the mean hospital LOS to be only modestly improved
(9.33.3 versus 9.93.5 days for the amiodarone and control
groups, respectively) with a pooled difference in hospital LOS of
0.6 days (95% CI 0.4-0.8, P<0.0001), which is consistent with
the 0.7-day difference we observed in our instrumental
variable analysis. This0.7-day difference will be of interest to
cardiac surgical programs interested in safely reducing LOS.
Ventricular Arrhythmias Following Cardiac
Surgery
In randomized control trials amiodarone use has been shown to
reduce rates of ventricular arrhythmias, and the pooled odds ratio
in the Bagshaw et al meta-analysis was 0.39 (95% CI 0.26-0.58,
P<0.0001).15Weobserved a higher rate of ventricular arrhythmias
associatedwith amiodarone use in the covariate-adjusted analysis
(4.3% versus2.8%,P<0.001) but noassociation in the instrumental
variable analysis. We also noted greater odds of ventricular
arrhythmia among those treated at hospitals with low perioper-
ative amiodarone use as compared with hospitals with high
perioperative amiodarone use. It is possible that administration of
amiodarone at these low-use perioperative hospitals reflects the
treatment of arrhythmias rather than prophylaxis for atrial
arrhythmias. It is also worth highlighting that in the PAPABEAR
trial, the overall rate of ventricular arrhythmias was only 1.5% (9/
601) comparedwith 3.1% (394/12 758) in our cohort.14 Thismay
be the result of differences in the underlying risk profile of patients
selected for clinical trials compared with those who receive
treatment in routine care. Although we went to great lengths to
exclude patients with an earlier history of atrial and ventricular
arrhythmias from the study (using earlier diagnoses and medica-
tion therapy), and our results reflect adjustment for numerous
potential confounders, it is also possible that the higher risk of
arrhythmia we observed in the conventional multivariable models
was the result of residual selection bias in which physicians
preferentially prescribed amiodarone to patients who were at
higher risk of ventricular arrhythmias. The fact that we did not
observe an association between amiodarone and ventricular
arrhythmias in the instrumental variable analysis, which was
performed to address concern about residual confounding by
unmeasured factors, is therefore reassuring.
Limitations
Although our study included a large number of patients from
hundreds of US hospitals and used state-of-the-art causal
inference methods to estimate the association between
amiodarone use and outcomes, our results should be viewed
in light of several limitations. First, because treatment
assignment was not random, there is a risk of residual
Table 3. Results of Instrumental Variable Analysis
Outcomes*
Marginal Patient
Risk Difference (95% CI) P Value
Atrial arrhythmias 0.11 (0.19, 0.04) 0.002
Ventricular arrhythmias 0.02 (0.04, 0.003) 0.09
Readmission (all cause)
within 1 mo
0.03 (0.03, 0.10) 0.31
In-hospital mortality 0.003 (0.016, 0.011) 0.67
LOS, mean (SD), days,
winsorized at 95th percentile
0.70 (1.39, 0.007) 0.048
Cost, mean (SD), US dollars,
winsorized at 95th percentile
3650 (2374, 9675) 0.23
LOS indicates length of stay.
*Adjusted for age, race, insurance payer, type of procedure, chronic lung disease, weight
loss, tobacco abuse disorder, loop diuretic on or before surgery day, statins on or before
surgery day, b-blockers on or before surgery day, hospital size, region, teaching status.
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selection bias that could be responsible for the association
between receipt of perioperative amiodarone and the out-
comes we studied. We undertook several strategies to
minimize these threats and to test the robustness of our
effect estimates. We employed careful inclusion and exclusion
criteria to replicate those used on earlier clinical trials. In
addition, we adjusted for numerous potential confounders,
including patient demographics, other medical therapies such
as b-blockers and statins, and important hospital character-
istics. To address concerns about residual unmeasured
confounding, we performed an instrumental variable analysis,
a common econometric technique used in comparative
effectiveness research.26,27 Second, because we used a
database based on hospital claims, we were unable to assess
the use of amiodarone before hospital admission with regard
to either dose or number of days of use before hospitalization.
Third, this study is based on highly detailed billing data using
ICD-9 codes, not chart review. We did not have information
about the circumstances or factors that led physicians to
prescribe amiodarone, and it is possible that some of the
patients received treatment with amiodarone for new arrhyth-
mias rather than for prevention. Although we excluded
patients with conditions that could provide an indication for
chronic amiodarone other than with the intent of preventing
atrial arrhythmias in the postoperative period, we had limited
information about medication dosing or specific amiodarone
protocols. Thus, we are unable to comment on the relative
benefits and risks associated with the timing of amiodarone
initiation. Fourth, we chose hospitals with high rates of
perioperative amiodarone as our instrument for the instru-
mental variable analysis. However, it is important to note that
even among these hospitals, only half of the patients actually
received amiodarone. A final limitation is that we did not have
access to long-term outcomes.
Conclusions
In patients undergoing elective cardiac surgery with no
previous history or treatment of atrial or ventricular arrhyth-
mias, perioperative amiodarone use was associated with a
lower risk of atrial arrhythmias and shorter LOS. It was not
associated with significant differences in mortality, hospital
cost, or readmission. These findings are consistent with
earlier randomized clinical trials and lend support to current
guideline recommendations.
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Table S1. ICD-9 diagnosis codes. 
  ICD-9 codes ICD-9 description 
Hypotension 458.29 Other iatrogenic hypotension 
    Post-operative hypotension 
  458.9 Hypotension, unspecified 
    Hypotension (arterial) NOS 
Bradycardia 427.81 Sinoatrial node dysfunction 
    Sinus bradycardia: 
    persistent 
    severe 
    Syndrome: 
    sick sinus 
    tachycardia-bradycardia 
    Excludes: 
    sinus bradycardia NOS (427.89) 
Heart block  426.0 Atrioventricular block, complete 
    Third degree atrioventricular block 
  426.1 Atrioventricular block, other and unspecified 
  426.10 Atrioventricular block, unspecified 
    Atrioventricular [AV] block (incomplete) (partial) 
  426.11 First degree atrioventricular block 
    Incomplete atrioventricular block, first degree 
    Prolonged P-R interval NOS 
  426.12 Mobitz (type) II atrioventricular block 
    Incomplete atrioventricular block: 
    Mobitz (type) II 
    second degree, Mobitz (type) II 
  426.13 Other second-degree atrioventricular block 
    Incomplete atrioventricular block: 
    Mobitz (type) I [Wenckebach's] 
    second degree: 
    NOS 
    Mobitz (type) I 
    with 2:1 atrioventricular response [block] 
    Wenckebach's phenomenon 
  426.2 Left bundle branch hemiblock 
    Block: 
    left anterior fascicular 
    left posterior fascicular 
  426.3 Other left bundle branch block 
    Left bundle branch block: 
    NOS 
    anterior fascicular with posterior fascicular 




 http://ahajournals.org by on Septem
ber 16, 2019
    main stem 
  426.4 Right bundle branch block 
  426.5 Bundle branch block, other and unspecified 
  426.6 Other heart block 
    Intraventricular block: 
    NOS 
    diffuse 
    myofibrillar 
    Sinoatrial block 
    Sinoauricular block 
Supraventricular 
tachycardias 427.0 
Paroxysmal supraventricular tachycardia 
    Paroxysmal tachycardia: 
    atrial [PAT] 
    atrioventricular [AV] 
    junctional 
    nodal 
Post-operative 
stroke 997.02   
Myocardial 
infarction 410.X1 initial episode of care 
Stroke 433.01 OCL BSLR ART W INFRCT 
  433.10 OCL CRTD ART WO INFRCT 
  433.11 OCL CRTD ART W INFRCT 
  433.21 OCL VRTB ART W INFRCT 
  433.31 OCL MLT BI ART W INFRCT 
  433.81 OCL SPCF ART W INFRCT 
  433.91 OCL ART NOS W INFRCT 
  434.00 CRBL THRMBS WO INFRCT 
  434.01 CRBL THRMBS W INFRCT 
  434.11 CRBL EMBLSM W INFRCT 
  434.91 CRBL ART OCL NOS W INFRC 
  436 CVA 
  430 SUBARACHNOID HEMORRHAGE 
  431 INTRACEREBRAL HEMORRHAGE 
Ventricular 
arrhythmias     
  427.1 Paroxysmal ventricular tachycardia 
    Ventricular tachycardia (paroxysmal) 
  427.4 Ventricular fibrillation and flutter 
  427.41 Ventricular fibrillation 
  427.42 Ventricular flutter 
Cardiogenic 
shock 785.50 Shock, unspecified 
  785.51 Cardiogenic shock 
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  V12.53 Sudden cardiac arrest 
  99.60 Cardiopulmonary resuscitation, not otherwise specified 
  99.63 Closed chest cardiac massage 
Pacemaker 37.70 Initial insertion of lead [electrode], not otherwise specified 
  37.71 Initial insertion of transvenous lead [electrode] into ventricle 
  37.72 
Initial insertion of transvenous leads [electrodes] into atrium and 
ventricle 
  37.73 Initial insertion of transvenous lead [electrode] into atrium 
  37.78 Insertion of temporary transvenous pacemaker system 
  37.80 
Insertion of permanent pacemaker, initial or replacement, type of 
device not specified 
  37.81 
Initial insertion of single-chamber device, not specified as rate 
responsive 
  37.82 Initial insertion of single-chamber device, rate responsive 
 37.83 Initial insertion of dual-chamber device 
 37.85 
Replacement of any type pacemaker device with single-chamber 
device, not specified as rate responsive 
 37.86 
Replacement of any type of pacemaker device with single-chamber 
device, rate responsive 
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